BDA-366 specifically targets the BH4 domain of Bcl2 BDA-366 and suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change.

Eptifibatide an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class is a cyclic heptapeptide constructed from 6 amino acids and a mercaptopropionyl residue.

4-Methylumbelliferyl-β-D-Glucopyranoside is used in the GCase activity assay based on the catalytic hydrolysis of 4-methylumbelliferyl β-D-glucopyranoside that releases the highly fluorescent 4-methylumbelliferyl (4-MU).